MON-736 - Impact of Reduced-Frequency Glucagon-Like Peptide-1 Receptor Agonist Therapy on Weight Loss and Body Composition: A Real-World 12-Month Study

Background
The glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for weight management and metabolic optimization typically administered once weekly. In our clinic, we follow recent guidelines by providing a comprehensive metabolic risk assessment for every patient. We identified a subgroup of patients for whom we hypothesize that a personalized reduced dosing frequency of GLP-1 receptor agonists therapy, may be more effective strategy for them.

Objective:
This study aimed to evaluate the impact of a personalized reduced-frequency dosing of GLP-1 receptor agonists (for more than once per week), on weight loss and body-composition changes during 12 months in adults with overweight or obesity.

Methods
A retrospective observational study was conducted on 35 adults (≥18 years) with overweight or obesity treated with GLP-1 receptor agonists at reduced frequency (more than once per week). Measurements were assessed at baseline and at 3, 6, and 12 months included weight, BMI (Body Mass Index), BFM (Body Fat Mass), LBM (Lean Body Mass), SMM (Skeletal Muscle Mass), and VF (Visceral Fat) using bioelectrical impedance analysis (InBody®️ 770). Percent changes and p-values were calculated at every follow-up, with statistical significance set at p< 0.05.

Results
35 participants were included. BMI decreased significantly at 3, 6, 9, and 12 months by -2.54% (p=0.002), -5.15% (p=0.028), -10.10% (p=0.027), and -6.10% (p=0.006), respectively. Significant reduction in Body Fat Mass at 3, 6, 9, and 12 months by -5.93% (p < 0.001), -13.15% (p=0.008), -23.68% (p=0.008), and -8.76% (p=0.009), respectively. Visceral Fat reduced significantly at 3, 6, 9, and 12 months by -5.81% (p < 0.001), -18.98% (p=0.015), -24.52% (p=0.011), and -6.92% (p=0.014), respectively. Mean body weight decreased progressively at 3, 6, 9, and 12 months by -2.52% (p < 0.001), -5.04% (p=0.002), -11.39% (p < 0.001), and -4.21% (p=0.009), respectively. No significant changes were observed in Soft Lean Mass (SLM) at 3, 6, 9, and 12 months (−0.18%, p=0.773; +4.16%, p=0.355; +1.59%, p=0.335; −0.72%, p=0.243, respectively). Skeletal muscle mass (SMM) also showed no significant change at 3, 6, 9, and 12 months (−0.18%, p=0.766; +4.35%, p=0.272; +2.06%, p=0.349; −1.30%, p=0.252, respectively) indicating preservation of muscle mass.

Conclusion
Our study demonstrates that the use of GLP-1 receptor agonists therapy at intervals longer than once weekly was associated with significant reductions in body weight, BMI, body fat mass, and visceral fat over 12 months. Lean and skeletal muscle mass was preserved. These finding are an early proof that a personalized de-escalation may be an effective therapy choice without sacrificing the beneficial outcomes.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*